Beam Therapeutics Inc. Common Stock (BEAM) is a publicly traded Healthcare sector company. As of May 20, 2026, BEAM trades at $27.21 with a market cap of $2.76B and a P/E ratio of -53.82. BEAM moved +3.06% today. Year to date, BEAM is +1.01%; over the trailing twelve months it is +52.73%. Its 52-week range spans $13.53 to $36.44. Analyst consensus is strong buy with an average price target of $49.91. Rallies surfaces BEAM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Beam Therapeutics Reports Durable Phase 1/2 Safety and Efficacy in 29 Patients: Beam Therapeutics presented additional Phase 1/2 single-dose data for BEAM-302 in 29 alpha-1 antitrypsin deficiency patients, highlighting detailed safety outcomes, durable efficacy and reduced neutrophil elastase activity. Based on FDA feedback, Beam plans to enroll ~50 more patients and initiate a pivotal cohort in H2 2026.
| Metric | Value |
|---|---|
| Price | $27.21 |
| Market Cap | $2.76B |
| P/E Ratio | -53.82 |
| EPS | $-0.50 |
| Dividend Yield | 0.23% |
| 52-Week High | $36.44 |
| 52-Week Low | $13.53 |
| Volume | 1.79M |
| Avg Volume | 0 |
| Revenue (TTM) | $164.01M |
| Net Income | $-65.04M |
| Gross Margin | 0.00% |
12 analysts cover BEAM: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $49.91.